PTGS2 and Alzheimer disease: Third, the failure of some COX-2 inhibitors in clinical trials for AD may be due to their selectivity for COX-2 over COX-1, and so, new non-selective COX inhibitors or COX-2 inhibitors with different mechanisms of action may be more effective (Scharf et al., 1999, Imbimbo, 2009).